SAN DIEGO, March 7, 2022 /PRNewswire/ — Rakuten Medical, Inc. (Rakuten Medical) has elected to discontinue using the “Illuminax” name and begin using a new, evolved name “Alluminox™” for our proprietary cancer photoimmunotherapy technology platform, which includes drugs, medical devices and other related technologies. This name change will take effect globally from April 1, 2022.
The new name “Alluminox™”, pronounced Ay-luminox, is derived from our aspiration to use the power of lighting to deliver what we hope will be a fatal blow to cancer cells. Our mission and overall aspirations are to help illuminate the future for cancer patients All in the world.
The original name, “Illuminox”, was challenged in the United States over trademark issues. Rakuten Medical wishes to use its available financial and human resources to advance our technology, to help deliver our treatments to patients and caregivers – rather than using our resources to engage in protracted litigation.
“Although we have a new name – Alluminox™ – for our proprietary technology platform, which combines the power of light with an investigational drug, device and other related components to develop innovative new cancer therapies, our corporate mission, ‘conquer cancer’, remains unchanged. Rakuten Medical will continue to strive to bring its innovative treatments to as many patients as possible, as quickly as possible. possible,” said Mickey Mikitani, CEO of Rakuten Medical, Inc.
About Rakuten Medical, Inc.
Rakuten Medical, Inc. is a global clinical-stage biotechnology company that develops and commercializes precision investigational cell-targeting therapies on its Illuminox™ platform, which in preclinical studies has been shown to induce rapid and selective cell killing and tumor necrosis. Apart from Japan, Illuminax therapies have not yet been approved as safe or effective by any regulatory authority. The company’s first drug developed on the Illuminox platform, ASP-1929, has received approval from the Japanese Ministry of Health, Labor and Welfare, and is currently undergoing a global phase clinical trial 3 for recurrent head and neck cancer. Rakuten Medical is committed to its mission to defeat cancer and aims to create a society where cancer patients can lead fulfilling lives. The company has offices in 5 countries, including United Stateswhere is its head office, Japan, the Netherlands, Taiwanand Switzerland. For more information, visit www.rakuten-med.com.
About the Illuminax™ Platform
The Illuminox platform is an experimental platform based on an anticancer therapy called photoimmunotherapy, which was developed by Dr. Hisataka Kobayashi and the team of the National Cancer Institute of United States. Rakuten Medical develops the Illuminax platform as a technology consisting of a drug, a device and other related components. The drug component of the platform consists of a targeting moiety conjugated to one or more dyes leading to selective binding to the cell surface. The component of the device consists of a light source that locally illuminates the targeted cells with non-thermal light to transiently activate the drug. Preclinical data have shown that this activation causes rapid and selective necrosis of the targeted cells by a biophysical process that compromises the membrane integrity of the targeted cells. The therapies developed on Illuminox can also result in local and systemic innate and adaptive immune activation due to immunogenic cell death of targeted cells and/or elimination of immunosuppressive elements in the microenvironment. Outside of Japan, Illuminax therapies have not yet been approved as safe or effective by any regulatory authority.
This press release contains forward-looking statements that fall within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements involve various risks, uncertainties and assumptions that could cause the business plans and results of Rakuten Medical differ from the results and expectations expressed in these statements. These “forward-looking statements” contain information about the status and development of our products, including ASP-1929, the Illuminax platform and IRDye® 700DX, as well as other regulatory and marketing clearance efforts, potential benefits, efficacy and safety of ASP -1929 and other therapies created using the Illuminax platform, and the status of regulatory filings. Approval and commercial success of these therapies may not be achieved, and results and effects shown in preclinical studies and data may not be replicated in clinical trials. These statements may include words such as “expect”, “believe”, “hope”, “estimate”, “seem”, “anticipate”, “intend”, “may”, “suggest”. , “plan”, “strategy”, “will”, “hopeful”, “excited”, “do”, “goals”, “develop” and similar expressions. Forward-looking statements are neither historical facts nor assurances of future performance. Further, Rakuten Medical’s partnership with Shimadzu does not imply any particular results or achievements for Rakuten Medical. These forward-looking statements are based on Rakuten Medical’s current beliefs, expectations and assumptions regarding the future of its business. , its future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to uncertainties, risks and changes of circumstances i inherent which are difficult to predict and many of which are beyond Rakuten Medical’s control. The actual results and financial condition of Rakuten Medical may differ materially from those indicated in the forward-looking statements. Accordingly, you should not rely on any such forward-looking statements. Additionally, this press release uses terms such as “hope”, “contribute”, and “expand” to express opinions about clinical trial data. The ongoing clinical trial studies involve various risks and uncertainties, in particular, issues that arise during the manufacturing stage of ASP-1929 or other product candidates, the occurrence of adverse events related to safety, situations in which therapeutic benefits are not demonstrated and other miscellaneous risks and uncertainties. , both reasonable and unreasonable. For this reason, actual results, including regulatory approvals and uncertainties in the commercialization process of ASP-1929 or other product candidates, may differ from published information. Except to the extent required by applicable law, we undertake no obligation to publicly update this statement or any other forward-looking statement, whether as a result of new information, future developments or events, changes in assumptions, changes in factors affecting forward-looking statements. If one or more forward-looking statements are updated, no inference should be drawn that additional updates will be made to such or other forward-looking statements.
Show original content to download multimedia:https://www.prnewswire.com/news-releases/rakuten-medical-announces-new-name-alluminox-for-its-proprietary-technology-platform-301496622.html
SOURCE Rakuten Medical, Inc.